Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis

GVHD prevention using a combination of post-transplantation cyclophosphamide in combination with abatacept, vedolizumab and Ruxolitinib in children and young adults with hematoloblastosis after myeloablative conditioning regimen with treosulfan/TBI, etoposide, fludarabine after HSCT from matched unrelated and haploidentical donors

Trial Details

NCT ID

NCT06756152

Phase

PHASE2 / PHASE3

Sponsor

Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

Conditioning regimen: Treosulfan 42 g/m2/course or total body irradiation 12 Gray/course, Etoposide 60 mg/kg , Fludarabine 150

Locations (sample)

Moscow, Russia|55.75204,37.61781

Key Eligibility Criteria

1\. Patients under the age of 21 years with following diseases:
acute lymphoblastic,
myeloblastic,
biphenotypic,

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →